FDA Determines Regulatory Review Period for FASLODEX Patent Extension

Summary

The Food and Drug Administration has published a notice determining the regulatory review period for FASLODEX, a human drug product, in response to a patent extension application submitted to the Director of Patents and Trademarks at the US Department of Commerce.